Clinical Trial

A Study of LY3439539 in Participants With Alzheimer's Disease

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to see how LY3439539 affects certain proteins found in the spinal fluid of participants with Alzheimer's disease. Participation in the study will last approximately 9 months with visits about once a month.
Protocol Amendment History 3 changes
notable Primary completion pushed: 2027-05 -> 2027-08 2026-07-21
minor Completion pushed: 2027-05 -> 2027-08 2026-07-21
critical Recruitment opened 2026-06-17
Trial Details
NCT Number NCT07598370
Lead Sponsor Eli Lilly and Company
Conditions Alzheimer Disease
Enrollment 30 participants
Start Date 2026-05-21
Primary Completion 2027-08 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2026-07-20